Science Highlights
Published on March 03, 2026
Eltrombopag for post-transplant thrombocytopenia
by Bone Marrow Transplantation
Kumar A, Singh A, Reljic T, et al. Efficacy of Eltrombopag for Treatment of Thrombocytopenia in the Setting of Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Bone Marrow Transplantation. 2025; (doi: 10.1038/s41409-025-02760-6).
Results of a systematic review and meta-analysis affirm eltrombopag as a viable intervention against thrombocytopenia, a complication of allogeneic hematopoietic cell transplantation (allo-HCT). Investigators scrutinized evidence from 16 published studies that observed the thrombopoietin receptor agonist in this setting, with a focus on the outcomes of platelet response and transfusion independence. Researchers measured the pooled response rate at 56% for platelet counts achieving >50 x 109/L, both when assessed independently and when evaluated as part of the composite endpoint. The pooled rate for platelet counts reaching >30 x 109/L was 47% when calculated under the composite scenario but increased to 72% as a standalone outcome. Eltrombopag was also associated with pooled overall survival of 68% but low rates of bleeding-related death (6%) and death from graft-versus-host disease/infection (19%).
Read More
![]()
Bone Marrow Transplantation